Category1 Category2 Category3

Woden Venture Capital Corp. (Woden), has entered into a letter of intent with ACCUM Therapeutics Inc., a biotechnology company, to acquire all ACCUM Therapeutics's outstanding shares for a consideration of CAD4.5 million (US$3.6 million). 

ID:5P58-M8X1-JD8N-R22G_0